Psoriatic arthritis
2 years ago
Abstr #1037 evaluated BASDAI vs ASDAS in PsA w/ axial dx
Both ASDAS & BASDAI showed
- strong correlation w/ pt pain & Global Assessment
- weak correlation in tender and swollen joint counts and enthesitis
#ACR22 @RheumNow #axSpA #PsA https://t.co/EunXIwzn3M
2 years ago
Valero et al. Combined biologics in PsA. @RheumNow #ACR22 Abstr1044 https://t.co/7nNf0Ktf0M https://t.co/CIE9BnBFvx
2 years ago
Can we predict PsA incidence and prevalence trends?
Germany long-term projection 2040
3 scenarios:
1. increase 5%/yr
2. stable
3. decrease 5%/yr.
Best scenario (3) = peak diagnoses in 2028. Are medical resources ready for it?
https://t.co/ws87zDukuM
Abs#1019 #ACR22 @Rheumnow https://t.co/dqkfrag0w2
2 years ago
Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0
2 years ago
#abst1012 #acr22 @rheumnow CASIPSA Study of SI CT in 48 PsA pts vs 48 controls. Disease duration 22.87 ± 14.95 y, 43.48 %HLA-B27+. higher prevalences of erosion in PsA (18%) preferentially located on the anterior and middle regions of the SIJs https://t.co/4dtJNCKf4I
2 years ago
axPsA and AS adult pts exhibit different genetic risk factors & serum IL-17 levels. GUS demonstrated significant pharmacodynamic effects and clinical improvement in axPsA and non-axPsA pts. Abs 1038 #ACR22 @RheumNow https://t.co/9Rjw7usO8J
2 years ago
JAK and TYK-2 inhibitors and indications in SpA:
● Tofacitinib ➣ Pan JAKi (AS, PsA)
● Baricitinib ➣ JAK1,2
● Upadacitinib ➣ JAK1 (AxSpA, PsA)
● Deucravacitinib ➣ TYK2 (PsA)
Carol Langford, Year in Review #ACR22 @RheumNow https://t.co/EMLEvptySS
2 years ago
Differences between #uveitis pattern in AS vs. PsA and IBD 👇
This is always asked to our rheum fellows during Kelley's hour 🤓
#ACR22 @RheumNow @rheumarhyme @trishiemd @RheumaRamblings @RheumaRambolMD https://t.co/gWxQ9xdb06
Minimal Disease Activity, MDA, criteria are used to evaluate PsA disease activity and response to treatment. For reference, MDA is defined as meeting ≥5 criteria: tender joint count ≤1, swollen joint…